ATXS
vs
S&P 500
ATXS
S&P 500
Over the past 12 months, ATXS has significantly outperformed S&P 500, delivering a return of +98 011% compared to the S&P 500's +16% growth.
Stocks Performance
ATXS vs S&P 500
Performance Gap
ATXS vs S&P 500
Performance By Year
ATXS vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Astria Therapeutics Inc
Glance View
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 29 full-time employees. The company went IPO on 2015-06-25. The Company’s lead product candidate is STAR-0215, is a potential monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen and airway. STAR-0215 is a monoclonal antibody inhibitor of plasma kallikrein, which is designed to provide long-acting attack prevention for HAE. The Company’s on-demand treatment of HAE therapy includes BERINERT, FIRAZYR, KALBITOR and RUCONEST. Its long-term preventative treatment of HAE therapy includes CINRYZE, HAEGARDA, TAKHZYRO and ORLADEYO.
